MYCOPHENOLATE MOFETIL VS CYCLOPHOSPHAMIDE IN SCLERODERMA ASSOCIATED INTERSTITIAL LUNG DISEASE(ILD) - SINGLE CENTER OBSERVATIONAL STUDY

被引：0
作者：
Bavaliya, M. [1 ]
Padmanabha, S. [1 ]
机构：
[1] Amrita Inst Med Scienece, Kochi, Kerala, India
来源：
INTERNAL MEDICINE JOURNAL | 2015年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
ARP85
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [41] Combination Therapy of Mycophenolate Mofetil and Pirfenidone vs. Mycophenolate Alone: Results from the Scleroderma Lung Study III
    Khanna, Dinesh
    Spino, Cathie
    Bernstein, Elana
    Goldin, Jonathan
    Tashkin, Donald
    Roth, Michael
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1045 - 1047
  • [42] Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease
    Lok, Stacey D.
    Wong, Alyson W.
    Khor, Yet H.
    Ryerson, Christopher J.
    Johannson, Kerri A.
    CHEST, 2022, 161 (06) : 1594 - 1597
  • [43] Malignancy Risk Associated with Mycophenolate Mofetil and Azathioprine in Patients with Fibrotic Interstitial Lung Disease
    Lok, S. D.
    Wong, A. W.
    Cox, G. P.
    Fell, C. D.
    Fisher, J. H.
    Gershon, A. S.
    Halayko, A. J.
    Hambly, N.
    Khalil, N.
    Kolb, M. R.
    Manganas, H.
    Marcoux, V
    Morisset, J.
    Assayag, D.
    Sadatsafavi, M.
    Shapera, S.
    To, T.
    Wilcox, P.
    Ryerson, C. J.
    Johannson, K. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [44] Mycophenolate mofetil for therapy-resistant interstitial lung disease associated with ulcerative colitis
    Treiber, G
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2000, 95 (12) : 3674 - 3675
  • [45] DOUBLE-BLIND COMPARISON OF MYCOPHENOLATE MOFETIL AND ORAL CYCLOPHOSPHAMIDE FOR TREATMENT OF SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE (SCLERODERMA LUNG STUDY [SLS] II): RATIONALE, DESIGN, METHODS, BASELINE CHARACTERISTICS AND PATIENT DISPOSITION
    Khanna, D.
    Roth, M.
    Furst, D.
    Clements, P.
    Goldin, J.
    Arriola, E.
    Kotlerman, J.
    Tseng, C. -H.
    Kim, G.
    Elashoff, R.
    Tashkin, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 507 - 507
  • [46] EFFICACY OF MYCOPHENOLATE MOFETIL (MMF) VERSUS ORAL CYCLOPHOSPHAMIDE (CYC) ON SKIN THICKNESS IN THE SCLERODERMA LUNG STUDY II
    Khanna, D.
    Tashkin, D.
    Furst, D. E.
    Tseng, C. -H.
    Wilhalme, H.
    Roth, M.
    Kafaja, S.
    Volkmann, E.
    Elashoff, R.
    Clements, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 525 - 525
  • [47] Correlation of Cough With Disease Activity and Treatment With Cyclophosphamide in Scleroderma Interstitial Lung Disease Findings From the Scleroderma Lung Study
    Theodore, Arthur C.
    Tseng, Chi-Hong
    Li, Ning
    Elashoff, Robert M.
    Tashkin, Donald P.
    CHEST, 2012, 142 (03) : 614 - 621
  • [48] The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)
    Clements, Philip J.
    Tashkin, Donald
    Roth, Michael
    Khanna, Dinesh
    Furst, Daniel E.
    Tseng, Chi-hong
    Volkmann, Elizabeth R.
    Elashoff, Robert
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [49] Double-Blind Comparison Of Mycophenolate Mofetil And Oral Cyclophosphamide For Treatment Of Scleroderma-Related Interstitial Lung Disease (scleroderma Lung Study [sls] Ii): Rationale, Design, Methods, Baseline Characteristics/intercorrelations And Patient Disposition
    Tashkin, D. P.
    Roth, M. D.
    Furst, D. E.
    Clements, P.
    Khanna, D.
    Goldin, J. G.
    Arriola, E.
    Kotlerman, J.
    Tseng, C. -H.
    Kim, G.
    Elashoff, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [50] A single center experience of rituximab for anti synthetase syndrome associated interstitial lung disease (ASS-ILD)
    Rathnapala, Amila
    Wing, Louise
    Benamore, Rachel
    David, Joel
    Hoyles, Rachel
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
12345